CA2744339A1 - Method for treating parkinson's disease - Google Patents

Method for treating parkinson's disease Download PDF

Info

Publication number
CA2744339A1
CA2744339A1 CA2744339A CA2744339A CA2744339A1 CA 2744339 A1 CA2744339 A1 CA 2744339A1 CA 2744339 A CA2744339 A CA 2744339A CA 2744339 A CA2744339 A CA 2744339A CA 2744339 A1 CA2744339 A1 CA 2744339A1
Authority
CA
Canada
Prior art keywords
bacteriophage
antibody
filamentous
filamentous bacteriophage
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2744339A
Other languages
English (en)
French (fr)
Inventor
Beka Solomon
Haim M. DIMANT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2744339A1 publication Critical patent/CA2744339A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2744339A 2008-11-24 2009-11-24 Method for treating parkinson's disease Pending CA2744339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
US61/117,446 2008-11-24
PCT/US2009/065659 WO2010060073A2 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Publications (1)

Publication Number Publication Date
CA2744339A1 true CA2744339A1 (en) 2010-05-27

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744339A Pending CA2744339A1 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Country Status (16)

Country Link
US (1) US20110286970A1 (enExample)
EP (2) EP2478911A1 (enExample)
JP (1) JP2012509672A (enExample)
KR (1) KR20110091778A (enExample)
CN (1) CN102223887B (enExample)
AU (1) AU2009316326A1 (enExample)
BR (1) BRPI0921557A2 (enExample)
CA (1) CA2744339A1 (enExample)
CO (1) CO6390112A2 (enExample)
IL (1) IL213120A0 (enExample)
MX (1) MX2011005430A (enExample)
NZ (1) NZ592928A (enExample)
RU (1) RU2011125971A (enExample)
SG (1) SG171791A1 (enExample)
WO (1) WO2010060073A2 (enExample)
ZA (1) ZA201104701B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
WO2009143470A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
TWI613212B (zh) 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
EA201791212A1 (ru) 2014-12-03 2018-01-31 Проклара Байосайенсиз, Инк. Полипептиды, содержащие аминокислотную последовательность модифицированного бактериофага g3p, в которой отсутствует сигнал гликозилирования

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344189T3 (es) * 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
AU2002223886A1 (en) * 2000-11-24 2002-06-03 Isis Innovation Limited Mixed fibrils
ES2392247T3 (es) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
EP1853299A4 (en) * 2005-01-14 2009-11-11 Univ California COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES
ES2363203T3 (es) * 2005-02-01 2011-07-26 Ramot At Tel-Aviv University Ltd. Método para tratar una inflamación asociada a depósitos amiloides y una inflamación cerebral que implica una microglia activada.
BRPI0707871A2 (pt) * 2006-02-15 2011-05-10 Ramot At Tel Aviv University veÍculos de exibiÇço de fago, composiÇço farmacÊutica ,e, mÉtodos para o tratamento ou a inbiÇço e para o diagnàsticos de uma doenÇa, distébio ou condiÇço cerebral
CA2659032A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
WO2009143470A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
JP2012509672A (ja) 2012-04-26
US20110286970A1 (en) 2011-11-24
ZA201104701B (en) 2012-09-26
KR20110091778A (ko) 2011-08-12
WO2010060073A3 (en) 2010-09-02
AU2009316326A1 (en) 2010-05-27
BRPI0921557A2 (pt) 2019-09-24
NZ592928A (en) 2012-12-21
SG171791A1 (en) 2011-07-28
IL213120A0 (en) 2011-07-31
CO6390112A2 (es) 2012-02-29
RU2011125971A (ru) 2012-12-27
WO2010060073A2 (en) 2010-05-27
EP2358377A2 (en) 2011-08-24
HK1162964A1 (en) 2012-09-07
CN102223887B (zh) 2013-11-06
EP2478911A1 (en) 2012-07-25
MX2011005430A (es) 2011-10-28
CN102223887A (zh) 2011-10-19

Similar Documents

Publication Publication Date Title
AU2020203867A1 (en) Cenicriviroc for the treatment of fibrosis
CA2752694A1 (en) Synthetic rna-based agonists of tlr7
CN119158034A (zh) 特异于结合素-4的双环肽配体
JP2016527286A5 (enExample)
NZ602824A (en) Sparc binding peptides and uses thereof
Haasbach et al. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus
JP2010540616A5 (enExample)
JP2010202664A5 (enExample)
WO2009039988A3 (en) Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
Hu et al. Japonicone A antagonizes the activity of TNF-α by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1
UA99914C2 (ru) Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
RU2011125971A (ru) Способ лечения болезни паркинсона
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
CN112135639B (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
US11993640B2 (en) Treating inflammatory lung disease
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2470656A1 (en) Corticotropin releasing factor 2 receptor agonists
CN103179987A (zh) 抑制p24蛋白产生或促进p24蛋白消除的方法和药物组合物
CN109790530A (zh) 治疗癌症的方法
CA2980329A1 (en) Self assembling molecules for targeted drug delivery
WO2018224614A1 (en) Vegf inhibitors for use for preventing and/or treating acne
WO2003041726A1 (en) Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
Catani et al. The Tat antagonist neomycin B hexa‐arginine conjugate inhibits gp‐120‐induced death of human neuroblastoma cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141110